Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 03 - 18    symbols : INCY    save search
Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation
Published: 2021-03-18 (Crawled : 22:00) - biospace.com/
NVS | News | $92.57 -0.55% 0.0% 910K twitter stocktwits trandingview |
Health Technology
 | | O: -0.56% H: 0.83% C: 0.02%
INCY | $52.82 0.19% 0.19% 1.8M twitter stocktwits trandingview |
Health Technology
 | | O: -1.05% H: 0.86% C: -1.4%
covid treatment results respiratory phase 3 syndros
Gainers vs Losers
66% 34%

Top 10 Gainers
AGBA | $1.02 155.0% 60.78% 120M twitter stocktwits trandingview |
Finance
INVO | $1.555 104.6% 51.13% 5M twitter stocktwits trandingview |
Health Technology
ISPC | $0.437 105.16% 49.53% 37M twitter stocktwits trandingview |
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 900K twitter stocktwits trandingview |

OST | $0.499 21.38% 45.26% 1.9M twitter stocktwits trandingview |

ZCMD | $2.44 78.1% 43.85% 330K twitter stocktwits trandingview |
Commercial Services
XPON | $3.1 60.62% 37.74% 16M twitter stocktwits trandingview |

TIRX | $0.7 44.39% 30.74% 58M twitter stocktwits trandingview |

BNTC | $6.92 44.17% 30.64% 3.5M twitter stocktwits trandingview |
Health Technology
GGE | $0.035 19.86% 29.3% 64M twitter stocktwits trandingview |

Your saved searches
Save your searches and get alerts when important news are released.